Logicbio Therapeutics Financials

Logicbio Therapeutics (LOGC) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Logicbio Therapeutics (LOGC) revenue declined by 100% year-over-year, from $43.0M to $0 in fiscal year 2025.

No, Logicbio Therapeutics (LOGC) reported a net income of -$23.0M in fiscal year 2025.

Logicbio Therapeutics (LOGC) reported diluted earnings per share of $-1.09 for fiscal year 2025. This represents a 62.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Logicbio Therapeutics (LOGC) has a return on equity of -17.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Logicbio Therapeutics (LOGC) generated -$16.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Logicbio Therapeutics (LOGC) had $218.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Logicbio Therapeutics (LOGC) had 27M shares outstanding as of fiscal year 2025.

Logicbio Therapeutics (LOGC) had a current ratio of 31.14 as of fiscal year 2025, which is generally considered healthy.

Logicbio Therapeutics (LOGC) had a debt-to-equity ratio of 0.64 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Logicbio Therapeutics (LOGC) had a return on assets of -10.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Logicbio Therapeutics (LOGC) had $77.0M in cash against an annual operating cash burn of $16.0M. This gives an estimated cash runway of approximately 58 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Logicbio Therapeutics (LOGC) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Logicbio Therapeutics (LOGC) has an earnings quality ratio of 0.70x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Logicbio Therapeutics (LOGC) scores 47 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.